Fundamentals of nuclear pharmacy

Fundamentals of Nuclear Pharmacy

Volumn , Issue , 2010, Pages 1-409

  Saha, Gopal B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892081129     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5860-0     Document Type: Book

References (185)

1. Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, November, 1985, CONF-851113.
2. Howell RW, Wessels BW, Loevinger R. The MIRD perspective. J Nucl Med. 1999; 40:3S-10S.
3. International Commission on Radiation Protection. Radiation dose to patients from radiopharmaceuticals (ICRP 80). ICRP Publications; 1999.
4. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York; 1991.
5. National Council on Radiation Protection and Measurements. General concepts for the dosimetry of internally deposited radionuclides (NCRP 84). NCRP Publications, Bethesda; 1985.
6. Reports of Medical Internal Radiation Dose (MIRD) Committee. Pamphlet Nos. 1-11. Society of Nuclear Medicine, New York; 1968-1977.
7. Stabin, MG. Fundamentals of Nuclear Medicine Dosimetry. Springer, New York, 2008.
8. U.S. Food and Drug Administration. Radioactive drugs and radioactive biological products. Fed Register. 1975; 40:144.
9. Zanzonico PB. Internal radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000; 41:297.
10. Cox PH. European legislation and its effects on the production of radiopharmaceu-ticals. In: Sampson CB, ed. Textbook of Radiopharmacy. Amsterdam: Gordon and Breach Science Publishers; 1999.
11. Directive 2003/94/EC, 2003. Official Journal L 262, 2003, p 22.
12. Directive 96/29/EURATOM, 1996. Official Journal L 159, 29, 1996, p 1.
13. Directive 2001/83/EC, 2001. Official Journal 311, 2001, p 267.
14. Directive 91/356/EEC, 1991. Directive 97/43/EURATOM, 1997.
15. Directive 65/65/EEC, 1965. Official Journal L 22, 1965, p 359.
16. Directive 75/319/EEC, 1975. Official Journal L 147, 1975, p 13.
17. Gollnick DA. Basic Radiation Protection Technology. 4th ed. Altadena, CA: Pacific Radiation Corporation; 2000.
18. International Commission on Radiological Protection. General Principles for the Radiation Protection of Workers. ICRP 75. New York: Elsevier; 1997.
19. International Commission on Radiological Protection. 1990 Recommendations of the ICRP. ICRP 60. New York: Elsevier; 1990.
20. National Council on Radiation Protection and Measurements. Limitation of Exposure to Ionizing Radiation (NCRP 116). Bethesda, MD: NCRP Publications; 1993.
21. National Council on Radiation Protection and Measurements. Maintaining Radiation Protection Records (NCRP 114). Bethesda, MD: NCRP Publications; 1992.
22. National Council on Radiation Protection and Measurements. Nuclear Medicine Factors Influencing the Choice and Use of Radionuclides in Diagnosis and Therapy (NCRP 70). Bethesda, MD: NCRP Publications; 1982.
23. National Council on Radiation Protection and Measurements. Radiation Protection and Allied Health Personnel (NCRP 105). Bethesda, MD: NCRP Publications; 1989
24. Nuclear Regulatory Commission. Consolidated Guidance About Material Licenses: Program Specific Guidance About Medical License. NUREA-1556. Vol 9, Rev. 2. Washington, DC: NRC; 2002.
25. Nuclear Regulatory Commission. Medical Use of Byproduct Material. 10CFR Part 35. Washington, DC: NRC; 2007.
26. Nuclear Regulatory Commission. Standards for Protection Against Radiation. 10CFR Part 20. Washington, DC: NRC; 1995.
27. Shapiro J. Radiation Protection. 4th ed. Cambridge, MA: Harvard University Press; 2002.
28. U.S. Food and Drug Administration. Food and Drug Administration Modernization Act of 1997. Rockville, MD: U.S. Food and Drug Administration; 1997.
29. U.S. Food and Drug Administration. Nuclear Pharmacy Guideline: Criteria for Determining When to Register as a Drug Establishment. Washington, DC: U.S. Food and Drug Administration; 1984.
30. U.S. Food and Drug Administration. Radioactive drugs and radioactive biological products. Fed Regist 40, 1975, p 144.
31. U.S. Food and Drug Administration. Regulations for In Vivo Radiopharmaceuticals for Diagnosing and Monitoring. 21CFR Part 315. Rockville, MD: U.S. Food and Drug Administration; 1999.
32. Zuckier L, Stabin M, Garetano G et al. Sensitivity of personal homeland security radiation detectors to medical radionuclides and implications for counseling of nuclear medicine patients. RSNA Annual Meeting. 2004; Abstract SSJ 19-01.
33. Chase GC, Rabinowitz JL. Principles of Radioisotope Methodology. 3rd ed. Minneapolis: Burgess; 1970.
34. Moss AJ Jr, Dalrymple GV, Boyd CM, eds. Practical Radioimmunoassay. St Louis: Mosby; 1976.
35. Odell WD, Daughaday WH, eds. Principles of Competitive Protein-Binding Assays. Philadelphia: Lippincott; 1974.
36. Rothfeld B, ed. Nuclear Medicine In Vitro. Philadelphia: Lippincott; 1974.
37. Thorell JI, Larson SM. Radioimmunoassay and Related Techniques. St Louis: Mosby; 1978.
38. Anthony CP, Thibodeau GA. Textbook of Anatomy and Physiology. St. Louis: Mosby; 1979.
39. 99mTc complexes for renal imaging. J Nucl Med. 1975; 16:357.
40. Atkins HL, Budinger TF, Lebowitz E, et al. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J Nucl Med. 1977; 18:133.
41. 18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res. 1990; 27:487.
42. Berman DS, Kiat HS, Van Train KF, et al. Myocardial perfusion imaging with technetium-99m-sestamibi: comparative analysis of imaging protocols. J Nucl Med. 1994; 35:681.
43. Cook GJR, Maisey MN, Britton KE, Chengazi V, eds. Clinical Nuclear Medicine. 4th ed. London: Hodder Arnold; 2006.
44. Delbeke D, Martin WH, Patton JA, et al., eds. Practical FDG Imaging. A Teaching File. New York: Springer; 2002.
45. 14C]-glucose in plasma and brain: influence on rate of glucose utilization determined with deoxyglucose method in rat brain. J Cereb Blood Flow Metab. 1993; 13:315.
46. Dilsizian V, Rocco TP, Freedman NMT, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium and stress-redistribution imaging. N Engl J Med. 1990; 323:141.
47. Dilsizian V, Bacharach SL, Beanlands RS et al. PET myocardial perfusion and metabolic clinical imaging. J Nucl cardiol. 2009; 16:651.
48. Early PJ, Sodee DB, eds. Principles and Practice of Nuclear Medicine. 2nd ed. St. Louis: Mosby; 1995.
49. Gould KL, Yoshida K, Hess MJ, et al. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med. 1991; 32:1.
50. Hauser W, Atkins HL, Nelson KG, et al. Technetium-99m-DTPA: a new radiophar-maceutical for brain and kidney imaging. Radiology. 1970; 94:679.
51. Henkin RE, Bara D, Dillehay GL, et al., eds. Nuclear Medicine. 2nd ed. Philadelphia: Mosby-Elsevier; 2006.
52. Higley B, Smith FW, Smith T, et al. Technetium-99m-1, 2-bis[bis(2-ethoxyethyl)-phos-phino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993; 34:30.
53. Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial Tl-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol. 1988; 12 (6):1456.
54. 123I-iodoamphetamine (IMP) tomography. J Nucl Med. 1982; 236:196.
55. Leveille J, Demonceau G, DeRoo M, et al. Characterization of technetium-99m-L, L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans. J Nucl Med. 1989; 30:1902.
56. McAfee JG, Grossman ZD, Gagne G, et al. Comparison of renal extraction efficiencies for radioactive agents in the normal dog. J Nucl Med. 1981; 22:333.
57. Mejia AA, Nakamura T, Masatoshi I, et al. Estimation of absorbed dose in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991; 32:699.
58. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging. 5th ed. Philadelphia: Saunders; 2006.
59. Ell PJ, Gambhir SS, Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed. Edinburgh: Churchill Livingstone; 2004.
60. Narra RK, Nunn AD, Kuczynski BL, et al. A neutral technetium-99m complex for myocardial imaging. J Nucl Med. 1989; 30:1830.
61. Phelps ME, Hoffman EJ, Selin C, et al. Investigation of F-18-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978; 19:1311.
62. Ruhlmann J, Oehr P, Biersack HJ, eds. PET in Oncology. Basics and Clinical Applications. Heidelberg: Springer; 1999.
63. 82Rb generator in clinical PET studies. Nucl Med Biol. 1990; 17:763.
64. Saha GB, MacIntyre WJ, Brunken RC, et al. Present assessment of myocardial viability by nuclear imaging. Semin Nucl Med. 1996; 26:315.
65. Sandler MP, Coleman RE, Walkers FJT, et al., eds. Diagnostic Nuclear Medicine. 4th ed. Baltimore: Lippincott; 2003.
66. Sapirstein LA, Vigt DG, Mandel MJ, et al. Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol. 1955; 181:330.
67. Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myo-cardial blood flow. Circulation. 1981; 63:1259.
68. Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HMPAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med. 1986; 27:171.
69. Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphi-cally the adrenergic nervous system in man. J Nucl Med. 1987; 28:1625.
70. 99mTc-suleso-mab in inflammation. J Nucl Med. 2003; 44:11.
71. Subramanian G, McAfee JG, Blair RJ, et al. Technetium 99m methylene diphospho-nate-a superior agent for skeletal imaging; comparison with other technetium complexes. J Nucl Med. 1975; 16:744.
72. Taylor A Jr, Eshima D, Christian PE, et al. Technetium-99m kit formulation; preliminary results in normal volunteers and patients with renal failure. J Nucl Med. 1988; 29:616.
73. Taylor A Jr, Eshima D, Fritzberg AR, et al. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986; 27:795.
74. Vallabhajosula S, Zimmerman RE, Pickard M, et al. Technetium-99m ECD: a new brain imaging agent. In vivo kinetics and biodistribution studies in normal human studies. J Nucl Med. 1989; 30:599.
75. 14C]deoxyglucose into glycogen in heart and skeletal muscle in vivo: Implications for the quantitation of tissue glucose uptake. Diabetes. 1997; 46:1106.
76. Wackers FJT, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxy-isobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30:301.
77. Wagner HN, Jr, Szabo Z, Buchanan JW. Principles of Nuclear Medicine. 2nd ed. Philadelphia: Saunders; 1995.
78. 67Ga localization in malignant disease. Nucl Med Biol. 1996; 23:745.
79. Bentola LA, Ebenstein Y, Weiss S. Quantum dots for in vivo small-animal imaging. J Nucl Med. 2009; 50:493.
80. Blasberg R. PET imaging of gene expression. Eur J Cancer. 2002; 38:2137.
81. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994; 35:1054.
82. Gambhir SS. Imaging gene expression. In: Schiepers C, ed. Diagnostic Nuclear Medicine. New York: Springer-Verlag; 1998:253.
83. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev. 2002; 2:683.
84. Gao X, Chung LW, Nic S. Quantum dots for in vivo molecular and cellular imaging. Methods Mol Biol. 2007; 374:135.
85. Luker GD, Piwnica-Worms D. Beyond the genome: molecular imaging in vivo with PET and SPECT. Acad Radiol. 2001; 8:4.
86. 99mTc-labeled organo-germanium nanoparti-cles and their in-vivo study as a spleen imaging agent. J Labelled Comp Radio-pharm. 2006; 49:1163.
87. Ross DW. Introduction to Molecular Medicine. New York: Springer-Verlag; 1992.
88. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005; 46:1210.
89. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging. 2002; 16:336.
90. Thakur ML, Lentle B. Joint SNM/RSNA Molecular Imaging Summit Statement. J Nucl Med. 2005; 46:11N. Urbain JLC. Reporter genes and imagene. J Nucl Med. 2001; 42:106.
91. Voss SD, Kruskal JB. Gene therapy: a primer for radiologists. Radiographics. 1998; 18:1343.
92. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001; 219:316.
93. Welch MJ, Hawker CJ, Wooley KL. The advantages of nanoparticles for PET. J Nucl Med. 2009; 50:1743.
94. Becker D, Hurley JR. Radioiodine treatment of hyperthyroidism. In: Sandler MP, Coleman RE, Walkers FJT, et al., eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore: Williams and Wilkins; 1996:943.
95. Boerman OC, van Schaijk FD, Oyen WJG, et al. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003; 44:400.
96. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacoki-netics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone pain. J Nucl Med. 1992; 33:1451.
97. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010; 40:122.
98. 131I). In: Sandler MP, Coleman RE, Walkers FJT, et al., eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore: Williams and Wilkins; 1996:959.
99. Maxon HR III, Smith HD. Radioiodine-131 in the diagnosis and treatment of meta-static well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990; 19:685.
100. Package inserts for Theraspheres and SIR-Spheres. Robinson RG, Preston DF, Schiéfelbein M, et al. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995; 274:420.
101. Salem R, Hunter RD. Yittrium-90-micrrospheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys. 2006; 66:583.
102. Cherry, SR, Sorensen JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003.
103. Friedlander G, Kennedy JW, Macias ES, Miller JM. Nuclear and Radiochemistry. 3rd ed. New York: Wiley; 1981.
104. Cherry, SR, Sorensen JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003.
105. Friedlander G, Kennedy JW, Macias ES, Miller JM. Nuclear and Radiochemistry. 3rd ed. New York: Wiley; 1981.
106. Bushberg JT, Seibert JA, Leidholdt EM Jr, Boone JM. The Essential Physics of Medical Imaging. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 2002.
107. Cherry SR, Sorensen JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003.
108. Hendee WR, Ritenour ER. Medical Imaging Physics. 4th ed. Hoboken: Wiley; 2002.
109. Saha GB. Physics and Radiobiology of Nuclear Medicine. 3rd ed. New York: Springer; 2006.
110. Friedlander G, Kennedy JW, Macias ES, Miller JM. Nuclear and Radiochemistry. 3rd ed. New York: Wiley; 1981.
111. Mirzadeh S, Mausner LF, Garland MA. Reactor-produced medical radionuclides. In: Vértes A, Nagy S, Klencsár Z, eds. Handbook of Nuclear Chemistry. Vol. 4. Dordrecht: Kluwer; 2003.
112. Poggenburg JK. The nuclear reactor and its products. Semin Nucl Med. 1974; 4:229.
113. Quaim SM. Cyclotron production of medical radionuclides. In: Vértes A, Nagy S, Klencsár Z, eds. Handbook of Nuclear Chemistry. Vol. 4. Dordrecht: Kluwer; 2003.
114. Saha GB. Miscellaneous radiotracers for imaging. In: Rayudu GVS, ed. Radiotracers for Medical Applications. Vol. II. Boca Raton, FL: CRC Press; 1983:119.
115. Saha GB, MacIntyre WJ, Go RT. Cyclotrons and positron emission tomography for clinical imaging. Semin Nucl Med. 1992; 22:150.
116. Colombetti LG. Radionuclide generators. In: Rayudu GVS, ed. Radiotracers for Medical Applications. Boca Raton, FL: CRC; 1983 : 133.
117. Eckelman WC, Coursey BM. Technetium-99m: generators, chemistry and preparation of radiopharmaceuticals. Int J Appl Radiat Isot. 1982; 33:793.
118. Guillaume M, Brihaye C. Generators for short-lived gamma and positron emitting radionuclides: current status and prospects. Nucl Med Biol. 1986; 13:89.
119. 99mTc radionuclide generators: I. Comparison of five analytical procedures for determination of total technetium in generator eluants. Appl Radiat Isot. 1986; 37:165.
120. 99mTc generators. Appl Radiat Isot. 1986; 37:173.
121. Knapp FF Jr, Butler TA, eds. Radionuclide Generators: New Systems for Nuclear Medicine Applications. Advances in Chemistry Series, No. 241. Washington, DC: American Chemical Society; 1984.
122. Lambrecht RM, Sajad M. Accelerator-derived radionuclide generators. Radiochim Acta. 1988; 43:171.
123. 4-carrier free. J Nucl Med. 1975; 16:639
124. 99mTc generator system for medical use. J Nucl Biol Med. 1976; 20:32.
125. 99mTc. J Nucl Med. 1964; 10:871.
126. Rösch F, Knap FF. Radionuclide generators. In: Vértes A, Nagy S, Klencsár Z, Rösch F, eds. Handbook of Nuclear Chemistry, Vol 4. Dordrecht: Kluwer; 2003.
127. 82Rb generator in clinical PET studies. Nucl Med Biol. 1990; 17:763.
128. United States Pharmacopeial Convention. U.S. Pharmacopeia 32 & National Formulary 27. Rockville, MD: United States Pharmacopeial Convention; 2009.United States Pharmacopeial Convention. U.S. Pharmacopeia 32 & National Formulary 27. Rockville, MD: United States Pharmacopeial Convention; 2009.
129. Clark MJ, Podbielski L. Medical diagnostic imaging with complexes of Tc-99m. Coord Chem Rev. 1987; 78:253.
130. Deutsch E, Nicolini M, Wagner HN, Jr eds. Technetium in Chemistry and Nuclear Medicine. Verona: Cortina International; 1983.
131. 99mTc-labeled radiopharmaceuticals. Semin Nucl Med. 1990; 20:5.
132. Dewanjee MK. Radioiodination: Theory, Practice and Biomedical Application. Boston: Kluwer Academic; 1992.
133. Eckelman WC, Steigman J, Paik CH. Radiopharmaceutical chemistry. In: Harpert J, Eckelman WC, Neumann RD, eds. Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical; 1996:213.
134. Jones AG, Davison A. The relevance of basic technetium chemistry to nuclear medicine. J Nucl Med. 1982; 23:1041.
135. Nicolini M, Bandoli G, Mazzi U, eds. Technetium in Chemistry and Nuclear Medicine. Verona: Cortina International; 1986.
136. Richards P, Steigman J. Chemistry of technetium as applied to radiopharmaceuticals. In: Subramanian G, Rhodes BA, Cooper JF, Sodd VJ, eds. Radiopharmaceuticals. New York: Society of Nuclear Medicine; 1975:23.
137. 99mTc-radiopharmaceutical. In: Welch MJ, ed. Radiopharmaceuticals and Other Compounds Labelled with Short-Lived Radionuclides. New York: Pergamon Press; 1977:83.
138. Steigman J, Eckelman WC. The Chemistry of Technetium in Medicine. Nuclear Medicine Series. NAS-NS-3204. Washington: National Head Press; 1992.
139. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med. 1989; 30:216.
140. Abrams MJ, Davison A, Jones AG, et al. Synthesis and characterization of hexakis (alkyl isocyanide) and hexakis (aryl isocyanide) complexes of technetium (I). Inorg Chem. 1983; 22:2798.
141. Callahan RJ, Froelich JW, McKusick KA, et al. A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication. J Nucl Med. 1982; 23:315.
142. 99mTc-labeled radiopharmaceuticals. Semin Nucl Med. 1990; 20:5.
143. Eckelman WC, Stiegman J, Paik CH. Radiopharmaceutical chemistry. In: Harpert J, Eckelman WC, Neumann RD, eds, Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical; 1996:217.
144. 0-1, 2-diethylenediylbis-L-cysteine. Neurolites and its metabolites. In: Nicolini M, Bandoli G, Mazzi U, eds. Techne-tium and Rhenium in Chemistry and Nuclear Medicine. Verona, Italy: Cortina International; 1990; 433.
145. Fritzberg AR, Kasina S, Eshima D, et al. Synthesis and biological evaluation of technetium-99m MAG3 as hippuran replacement. J Nucl Med. 1986; 27:11.
146. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986; 27:235.
147. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium and technetium. Semin Nucl Med. 1990; 20:80.
148. 15O-labelled butanol via organoborane chemistry. Appl Radiat Isot. 1985; 36:853.
149. Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radio-pharmaceutical for myocardial perfusion imaging. J Nucl Med. 1993; 34:222.
150. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256:495.
151. Loberg MD, Cooper M, Harvey E, et al. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med. 1976; 17:633.
152. Luxen A, Bida GT, Phelps ME, et al. Synthesis of enantiomerically pure D and L 6-[F-18] fluorodopa and in vivo metabolites via regioselective fluorodemercuration. J Nucl Med. 1987; 28:624.
153. 18F] FLT). J Radioanal Nucl Chem. 2000; 243:843.
154. 15O-Water constant infusion system for clinical routine application. J Labelled Comp Radiopharm. 1986; 23:1209.
155. Nosco D, Beaty-Nosco JA. Chemistry of technetium radiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coord Chem Rev 1999; 184: 91. Package inserts of various kits available from commercial suppliers.
156. 99mTc-hexamethyl propylene amine oxime for labeling leukocytes and imaging inflammation. Lancet. 1986; 2:946.
157. Sodd VJ, Allen DR, Hoagland DR, et al., eds. Radiopharmaceuticals II. New York: Society of Nuclear Medicine; 1979.
158. Stöcklin G, Pike VW, eds. Radiopharmaceuticals for Positron Emission Tomography. Dordrecht: Kluwer; 1993.
159. ten Berge RJM, Natarajan AT, Hardenman MR, et al. Labeling with indium-111 has detrimental effects on human lymphocytes. J Nucl Med. 1983; 24:615.
160. Thakur ML, Coleman RE, Welch MJ. Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution and comparison with gallium-67 citrate in dogs. J Lab Clin Med. 1977; 82:217.
161. Troutner DR, Volkert WA, Hoffman TJ, et al. A neutral lipophilic complex of Tc-99m with a multidentate amine oxime. Int J Appl Radiat Isot. 1984; 35:467.
162. United States Pharmacopeial Convention. U.S. Pharmacopeia 32 & National Formulary 27. Rockville, MD: United States Pharmacopeial Convention; 2009.
163. Welch MJ, ed. Radiopharmaceuticals and Other Compounds Labelled with ShortLived Radionuclides. New York: Pergamon Press; 1977.
164. Welch MJ, Redvanly CS, eds. Handbook of Radiopharmaceuticals. Radiochemistry and Applications. Hoboken, NJ: Wiley; 2003.
165. Zolle I, ed. Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine. New York: Springer; 2007.
166. Zuckier LS, Rodriguez LD, Scharff MD. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med. 1990; 20:166.
167. Avis KE, Leuchuk JW. Parenteral preparations. In: Avis KE, Lieberman HA, and Lachman L, eds. Remington: The Science and Practice of Pharmacy. 21st ed. Baltimore, MD: Lippincott, Williams and Wilkins; 2005.
168. Bobinet DD, Williams GC, Cohen MB. Comparison of commercial pyrogen testing laboratories. Am J Hosp Pharm. 1976; 33:801.
169. 99mTc-labeled radiopharmaceuticals. Semin Nucl Med 1990; 20:5.
170. 99mTc-radio-pharmaceuticals. Appl Radiol. 1977; 6:211.
171. Centre for Drug Evaluation and Research (CDER). Guideline on validation of the Limulus Amebocyte Lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. Rockville, MD: U.S. FDA; 1987.
172. 99mTc-labelled bone-scanning agents. Eur J Nucl Med. 1976; 1:15.
173. 99mTc-labeled radio-pharmaceuticals. Eur J Nucl Med. 1977; 2:97.
174. Meyer GJ, Coenen HH, Waters SL, et al. Quality assurance and quality control of short-lived radioharmaceuticals for PET. In: Stöcklin G, Pike VW, eds. Radio-pharmaceuticals for Positron Emission Tomography: Methodical Aspects. Dordrecht, Netherlands: Kluwer; 1993: 91.
175. 99mTc- radiopharmaceuticals-a practical guide. New York: Society of Nuclear Medicine; 1984.
176. United States Pharmacopeial Convention. U.S. Pharmacopeia 32 & National Formulary 27. Rockville, MD: The United States Pharmacopeial Convention; 2009.
177. Callahan RJ. The role of commercial nuclear pharmacy in the future practice of nuclear medicine. Semin Nucl Med. 1996; 26:85.
178. Cox PH, Coenen HH, Deckart H, et al. Report and recommendations on the requirements of postgraduate training in radiopharmacy and radiopharmaceutical chemistry 1989. Eur J Nucl Med. 1990; 17:203.
179. Elliot AT, Hilditch TE, Murray T, McNulty H. The design and construction of a central radiopharmacy. Nucl Med Commun. 1993; 14:328.
180. Guidelines for the preparation of radiopharmaceuticals in hospitals Special report no. 11. London: British Institute of Radiology; 1979.
181. Kawada TK, Tubis M, Ebenkamp T, Wolf W. Review of nuclear pharmacy practice in hospitals. Am J Hosp Pharm. 1982; 39:266.
182. Ponto JA, Hung SC. Nuclear pharmacy part II: nuclear pharmacy practice today. J Nucl Med Technol. 2000; 28:76.
183. Rhodes BA, Hladik III WB, Norenberg JP. Chinical radiopharmacy: principles and practices. Semin Nucl Med. 1996; 26:77.
184. Shaw SM, Ice RD. Nuclear pharmacy. Part I, emergence of the specialty of nuclear pharmacy. J Nucl Med Technol. 2000; 28:8.
185. The United States Pharmacopeial Convention. United States Pharmacopeia 32 and National Formulary 27. Chapter 〈797〉 pharmaceutical compounding-sterile preparations. Rockville, MD: The United States Pharmacopeial Convention;